Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 46.22 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 17.62 | Oscillator | Buy |
| Williams %R (14) | -78.55 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.09 (Hist -0.22) | Oscillator | Strong Sell |
| Average Directional Index (14) | 15.92 (+DI 18.2 / -DI 22.4) | Trend | Neutral |
Current price $11.82
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 11, 26 |
| EMA 20 | 12.29 | MA | Strong Sell |
| SMA 20 | 12.82 | MA | Strong Sell |
| EMA 50 | 11.55 | MA | Buy |
| SMA 50 | 12.15 | MA | Sell |
| SMA 200 | 6.64 | MA | Strong Buy |
| Truist Securities |
| maintain |
| Buy |
| Buy |
| Aug 6, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Aug 6, 26 | Stifel | maintain | Buy | Buy |
| Jul 7, 26 | Benchmark | upgrade | Hold | Buy |
| Nov 7, 25 | Leerink Partners | downgrade | Outperform | Market Perform |
| Aug 8, 25 | Stifel | maintain | Buy | Buy |
| Jul 14, 25 | Keybanc | maintain | Overweight | Overweight |
| May 16, 25 | Truist Securities | maintain | Buy | Buy |
| May 9, 25 | Stifel | maintain | Buy | Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Aug 24, 2026 | 2026-08-24 17:21:48 | View |
| 4 | Aug 18, 2026 | 2026-08-18 14:45:24 | View |
| 4 | Aug 14, 2026 | 2026-08-14 12:04:25 | View |
| 4 | Aug 14, 2026 | 2026-08-14 11:50:16 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 16:33:34 | View |
| 424B5 | Aug 13, 2026 | 2026-08-13 16:31:35 | View |
| 4 | Aug 13, 2026 | 2026-08-13 15:01:43 | View |
| 424B5 | Aug 11, 2026 | 2026-08-11 16:59:25 | View |
| 8-K | Aug 10, 2026 | 2026-08-10 07:49:17 | View |
| 8-K | Aug 7, 2026 | 2026-08-07 16:43:59 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ABCL | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -21.9x | 4.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -17.8x | EPS est. -0.66 | Discount |
| Price / Book | 4.0x | 1.9x | Elevated |
| Price / Sales | 57.9x | 20.7x | Elevated |
| EV / EBITDA | -22.8x | 1.1x | Discount |
| Return on equity | -17.5% | — | Weak |
| Gross margin | 75.0% | 87.2% | In line |
| Debt / Equity | 0.15 | 0.08 | Conservative |
| Piotroski / Altman Z | 3/9 | Z 5.35 | Safe zone |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 24, 26 | Hayden Michael R | director | P-Purchase | 53,613 @ $10.64 | $570.4K |
| Aug 18, 26 | Montalbano John S. | director | P-Purchase | 10,000 @ $11.03 | $110.3K |
| Aug 14, 26 | Booth Andrew | officer: Chief Financial Officer | P-Purchase | 37,200 @ $10.32 | $383.9K |
| Aug 12, 26 | Hayden Michael R | director | P-Purchase | 46,387 @ $10.37 | $481.0K |
| Aug 11, 26 | Hayden Michael R | director | G-Gift | 50,000 | — |
| Jul 1, 26 | Seely Lynn | director | A-Award | 152,207 @ $7.85 | $1.19M |
| Jun 30, 26 | Seely Lynn | director: | 0 | — | |
| Jul 1, 26 | Sandor Victor | director | A-Award | 152,207 @ $7.85 | $1.19M |
Stock news · updated daily
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, five have issued a buy recommendation and one
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,805,309 shares of the company's stock, valued at approximately $29,872,000. BlackRock Inc. owned 1.25% of AbCellera
AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -0.16 | -0.18 | Miss -9.8% | $4.05M |
| May 11, 2026 | -0.22 | -0.14 | Beat 36.4% | $8.31M |
| Feb 24, 2026 | -0.18 | -0.03 | Beat 83.3% | $44.90M |
| Nov 6, 2025 | -0.17 | -0.19 | Miss -11.8% | $8.96M |
| Aug 7, 2025 | -0.17 | -0.12 | Beat 29.4% | $17.08M |
| May 8, 2025 | -0.17 | -0.15 | Beat 11.8% | $4.24M |
